Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018. Immune related adverse event (irAE) is occurred in various organs and is suggestive to be related...
Main Authors: | Jun Sakakibara-Konishi, Mineyoshi Sato, Michiko Takimoto Sato, Kohei Kasahara, Masahiro Onozawa, Hidenori Mizugaki, Eiki Kikuchi, Hajime Asahina, Naofumi Shinagawa, Satoshi Konno |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Respiratory Medicine Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S221300712030383X |
Similar Items
-
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
by: Kazuya Tsubouchi, et al.
Published: (2020-04-01) -
Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
by: Nobukazu Fujimoto, MD, PhD, et al.
Published: (2021-03-01) -
Advances in Immunotherapy of Malignant Pleural Mesothelioma
by: Liao D, et al.
Published: (2021-08-01) -
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
by: Vilde Drageset Haakensen, et al.
Published: (2021-05-01) -
Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials
by: Joanne M. Mankor, et al.
Published: (2020-12-01)